Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/05
A23L-001/305
A61K-008/31
A61K-008/34
A61K-031/015
A61Q-017/04
A61Q-019/00
A61Q-019/04
A61K-045/06
출원번호
US-0259020
(2014-04-22)
등록번호
US-9192587
(2015-11-24)
발명자
/ 주소
Gierhart, Dennis L.
Fox, Joseph A.
출원인 / 주소
ZeaVision, LLC
대리인 / 주소
Nixon Peabody LLP
인용정보
피인용 횟수 :
0인용 특허 :
47
초록▼
Zeaxanthin is ingested orally at suitable dosages that gives skin a darker tint that emulates a healthy suntan and that reduces the severity of unwanted skin discoloration or irregularities. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient
Zeaxanthin is ingested orally at suitable dosages that gives skin a darker tint that emulates a healthy suntan and that reduces the severity of unwanted skin discoloration or irregularities. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan, a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns, and an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. The topical application of zeaxanthin can further enhance the darkening of the skin and reduce the severity of unwanted skin discoloration or irregularities.
대표청구항▼
1. A method of reducing the incidence or severity of an unwanted skin discoloration or irregularity, comprising: ingesting, over a period of time, at least 10 milligrams per day of zeaxanthin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tabl
1. A method of reducing the incidence or severity of an unwanted skin discoloration or irregularity, comprising: ingesting, over a period of time, at least 10 milligrams per day of zeaxanthin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the oral formulation being predominantly present in the form of the R—R stereoisomer of zeaxanthin; andduring the period of time, applying a topical formulation to the skin at a location of the unwanted skin coloration or irregularity so as to reduce the severity of the unwanted skin coloration or irregularity on the skin, the topical formulation being in the form that is one of a group consisting of a lotion, an ointment, or a cream, the topical formulation including zeaxanthin. 2. The method of claim 1, wherein the topical formulation includes a permeation-enhancing agent to increase permeation of the zeaxanthin from the topical formulation into epidermal tissue layers of the skin. 3. The method of claim 2, wherein the permeation-enhancing agent is dimethyl sulfoxide. 4. The method of claim 1, wherein the period of time is at least 1 week. 5. The method of claim 1, wherein the oral formulation further includes at least one oil. 6. The method of claim 5, wherein the oral formulation includes at least one second active ingredient selected from the group consisting of melanocyte-stimulating hormone and analogs, non-zeaxanthin carotenoids, tyrosine, green tea extract, lutein, lipoic acid, and selenomethionine. 7. The method of claim 5, wherein the oral formulation includes a green tea extract and zinc. 8. The method of claim 1, wherein the topical formulation further includes at least one of dihydroxyacetone, erythrulose, or tyrosine. 9. The method of claim 1, wherein the oral formulation provides at least about 20 milligrams per day of zeaxanthin and the zeaxanthin is the predominate carotenoid in the oral formulation. 10. The method of claim 1, wherein the oral formulation provides at least about 20 milligrams per day of zeaxanthin, and further includes a plurality of vegetable oils, zinc, and green tea extract. 11. The method of claim 1, wherein the zeaxanthin is the predominate carotenoid in the oral formulation. 12. The method of claim 11, wherein the oral formulation further includes lutein. 13. A method of reducing the incidence or severity of an unwanted skin discoloration or irregularity, comprising: ingesting, over a period of time, at least 20 milligrams per day of zeaxanthin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the oral formulation being predominantly present in the form of the R—R stereoisomer of zeaxanthin; andduring the period of time, applying a topical formulation to a location on the skin having the unwanted skin discoloration or irregularity, the topical formulation being in the form that is one of a group consisting of a lotion, an ointment, or a cream, the topical formulation including zeaxanthin, andwherein the combination of the ingesting and the applying reduces the incidence or severity of an unwanted skin discoloration or irregularity. 14. The method of claim 13, wherein the topical formulation includes a permeation-enhancing agent. 15. The method of claim 14, wherein the topical formulation further includes at least one of dihydroxyacetone, erythrulose, or tyrosine. 16. The method of claim 13, wherein the oral formulation further includes a plurality of oils, zinc, and green tea extract. 17. The method of claim 13, wherein the zeaxanthin is the predominate carotenoid in the oral formulation. 18. A method of reducing the incidence or severity of an unwanted skin discoloration or irregularity, comprising: ingesting, over a period of time, at least 20 milligrams per day of zeaxanthin, the ingested zeaxanthin being in an oral formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin being the predominate carotenoid in the oral formulation, the zeaxanthin being predominantly present in the form of the R—R stereoisomer of zeaxanthin, the oral formulation including at least one vegetable oil and at least one second active ingredient, the at least one second active ingredient being selected from the group consisting of melanocyte-stimulating hormone and analogs, non-zeaxanthin carotenoids, tyrosine, green tea extract, lutein, lipoic acid, and selenomethionine. 19. The method of claim 18, wherein the at least one second active ingredient is green tea extract.
Tsubokura Akira (Kawasaki JPX) Yoneda Hisashi (Yokohama JPX) Takaki Mikihiro (Kawasaki JPX) Kiyota Takashi (Yokohama JPX), Bacteria belonging to new genus process for production of carotenoids using same.
Ausich Rodney L. (Glen Ellyn IL) Brinkhaus Friedhelm Luetke (Lisle IL) Mukharji Indrani (Evanston IL) Proffitt John H. (Oak Park IL) Yarger James G. (St. Charles IL) Yen Huei-Che Bill (Naperville IL), Biosynthesis of zeaxanthin and glycosylated zeaxanthin in genetically engineered hosts.
Liao Hans H. (Madison WI) Medwid Richard D. (Fort Collins CO) Heefner Donald L. (Longmont CO) Sniff Kathleen S. (Arvada CO) Hassler Randal A. (Lafayette CO) Yarus Michael J. (Boulder CO), Carotenoid producing culture using Nespongiococcum excentricum.
Garnett Kevin M. ; Gierhart Dennis L. ; Guerra-Santos Luis H., Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat or prevent retinal degeneration in humans.
Horn Dieter (Heidelberg DEX) Schmidt Hans W. (Mannheim DEX) Ditter Walter (Heidelberg DEX) Hartmann Horst (Boehl-Iggelheim DEX) Lueddecke Erik (Mutterstadt DEX) Schmieder Klaus (Frankenthal DEX), Preparation of finely divided pulverulent carotinoid and retinoid compositions.
Paust Joachim,DEX ; Kriegl Wolfgang,DEX ; Hartmann Horst,DEX, Preparation of pure trans- and cis-4-Hydroxy-2,2,6-trimethylcyclohexan-1-one from isomerc mixtures.
Khachik Frederick (Beltsville MD), Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof.
Schneider Joachim U. (Weisenheim DEX) Schumacher Horst (Bobenheim DEX) Bewert Wolfgang (Frankenthal DEX) Gaus Guenter (Biblis DEX) Rheude Udo (Otterstadt DEX), Stable vitamin and/or carotenoid products in powder form, and the preparation thereof.
Khachik Frederick (Beltsville MD) Beecher Gary R. (Laurel MD) Li Betty W. (Mitchellville MD), Synthesis of (all-E)-2,7,-dimethylocta-2,4,6-triene-1,8-dial13C4.
Baranowitz Steven (85 Tices La. - Apt. 39 East Brunswick NJ 08816) Brookner Andrew (25 Spenser Dr. Short Hills NJ 07078), Treatment of age related macular degeneration with beta-carotene.
Orndorff Steve A. (Arvada CO) Campbell Elizabeth A. (Evans CO) Medwid Richard D. (Fort Collins CO), Zeaxanthin producing strains of Neospongiococcum Excentricum.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.